Try our Advanced Search for more refined results
Life Sciences
-
January 28, 2026
Robins Kaplan Takes Aim At Benicar MDL Fees Suit In NJ
Robins Kaplan LLP told a New Jersey federal court Wednesday that a suit over fees the firm collected in multidistrict litigation over blood pressure medication should be thrown out, saying it "parrot[s]" claims from earlier suits that were already dismissed.
-
January 28, 2026
Generics Makers Want Hospital Drug Data In Price-Fixing MDL
A group of 150 hospitals suing generic-drug makers for alleged price fixing in multidistrict litigation should hand over data on their drug purchases, the drugmakers have told a Pennsylvania federal court, arguing they don't sell directly to the hospitals and therefore have no records themselves.
-
January 28, 2026
3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit
The Third Circuit on Wednesday pressed attorneys defending Quest Diagnostics Inc.'s pretrial defeat of a proposed class action from workers who alleged that their 401(k) savings were drained by underperforming investment funds, spotlighting the parties' disagreement over whether the lab company followed its own investment policy statement.
-
January 27, 2026
Ohio PBM Suit Belongs In Federal Court, 6th Circ. Rules
The Sixth Circuit on Tuesday ruled that Ohio's lawsuit accusing pharmacy benefit managers of driving up prescription prices through rebate schemes belongs in federal court, saying in an opinion recommended for publication that the suit imposes liability on conduct undertaken at the direction of a federal officer.
-
January 27, 2026
Lasik Provider Can't Shake Wiretap Claims In Tracking Row
The operator of a laser eye surgery website must face a proposed class action alleging it illegally shared patients' confidential medical information with Meta, a California federal judge ruled, finding that the plaintiff could continue to press allegations under state and federal wiretap law.
-
January 27, 2026
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial
Artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. claimed a doctor in charge of a clinical trial site in Florida tried to cover up a failure to report an adverse event by submitting a fraudulent email to a federal inspector, according to a suit filed in Florida state court.
-
January 27, 2026
Kelley Drye Adds Ex-23andMe, Facebook Privacy Pros
Kelley Drye & Warren LLP said Monday it is boosting its privacy and information security practice with the addition of a former 23andMe attorney in California and a former Facebook attorney in Texas.
-
January 27, 2026
Medtronic Rival's VP Says Docs Praised Device But Didn't Buy
A vice president in charge of sales at Applied Medical testified Tuesday in a California federal trial over his company's antitrust claims against Medtronic, and said the overwhelmingly positive feedback Applied received from surgeons who used its advanced bipolar devices often didn't result in sales.
-
February 12, 2026
Law360 Seeks Members For Its 2026 Editorial Boards
Law360 is looking for avid readers of our publications to serve as members of our 2026 editorial advisory boards.
-
January 27, 2026
Biotech Fundraising A Good Sign For Public Markets
At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.
-
January 27, 2026
CBP's Medical Care Oversight Needs Improvement, GAO Says
A report issued by the U.S. Government Accountability Office found that U.S. Customs and Border Protection sometimes failed to provide proper medical oversight for certain people in its custody, violating its own policies and guidance for medical care.
-
January 27, 2026
White House Pushed To Back PTAB Rule Change Proposal
Two groups representing inventors and startups have thrown their support behind the U.S. Patent and Trademark Office's proposal to limit America Invents Act patent reviews, saying it will give patent owners certainty and also protect against foreign challenges to domestic patents.
-
January 27, 2026
Investors Say Teva Can't Get Early Win In Price-Fixing Suit
Investors guided by Highfields Capital told a Connecticut federal court that Teva Pharmaceuticals can't escape their claims that its alleged collusion with other drugmakers to artificially inflate the price of generic drugs also inflated stock prices, reasoning that Teva executives falsely attributed the company's performance to factors other than the alleged price-fixing.
-
January 27, 2026
Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.
-
January 26, 2026
Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL
Generic-drug makers sought to defeat a bid to certify proposed classes comprising thousands of pharmacies that indirectly purchased and resold generics at the center of sprawling price-fixing litigation, telling a Pennsylvania federal court Monday that certification would result in an "unmanageable trial."
-
January 26, 2026
Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict
Masimo has urged a California federal court to turn down Apple's request for relief from its $634 million trial loss in the companies' patent infringement fight over the Apple Watch, arguing that the company has made "extraordinarily untimely" attempts to change the meaning of "patient monitor."
-
January 26, 2026
Ill. Judge Trims False Ad Suit Over Abbott Formula
An Illinois federal judge Friday dismissed several claims in a putative class action alleging Abbott Laboratories falsely advertised its toddler drinks sold under the Similac brand as nutritionally proper for children ages 12 months to 36 months, but largely allowed the parents' complaint to move forward.
-
January 26, 2026
Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics
A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.
-
January 26, 2026
O'Melveny Brings On Proskauer M&A Pro In California
O'Melveny & Myers LLP announced Monday that it added a corporate dealmaker to its Newport Beach, California, office from the Los Angeles office of Proskauer Rose LLP.
-
January 26, 2026
Zenas BioPharma Slams Investor's Revamped Fraud Claim
Zenas BioPharma has asked a Massachusetts federal judge to toss a putative investor class action targeting pre-initial public offering statements about the company's spending, saying it didn't hide that it had ramped up investment in research and development.
-
January 26, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up the week with a slate of high-stakes deal challenges, governance rulings and oversight decisions, including an emergency bid to block a $10.9 billion bank merger, a state Supreme Court reversal reshaping stockholder agreement litigation and a major opinion allowing sexual misconduct oversight claims to proceed.
-
January 23, 2026
DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.
A D.C. Circuit panel revived a lawsuit Friday accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorism in Iraq, saying the victims behind the case have adequately alleged that the companies' participation was conscious and voluntary.
-
January 23, 2026
Paraquat, J&J Talc Litigation Headline Philly's 2026 Mass Torts
Cases concerning illnesses stemming from the herbicide paraquat and talcum power are kicking off 2026 in Philadelphia's mass tort system, pitting corporate powerhouses like Chevron, Syngenta and Johnson & Johnson against the city's perceived plaintiff-friendly juries.
-
January 23, 2026
Heart Valve Deal Was Blocked Over Innovation Concerns
The D.C. federal court ruling earlier this month that upended a deal for Edwards Lifesciences Corp. to purchase JenaValve Technology Inc. was based on concerns that the deal would reduce innovation by eliminating competition for a heart valve treatment that's still being developed, according to a ruling unsealed on Friday by the judge who issued it.
-
January 23, 2026
Cartiva Hid Toe Implant Safety Info, Pa. Woman's Suit Claims
Cartiva Inc. was sued Thursday in Pennsylvania federal court by a woman who claims that she was injured by a recalled defective toe implant device and that the company has concealed its safety data from regulators and medical providers.
Expert Analysis
-
Series
Law School's Missed Lessons: Mastering Time Management
Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.
-
Pharma Copay Programs Raise Complex Economic Questions
The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.
-
State False Claims Acts Can Help Curb Opioid Fund Fraud
State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.
-
Beaming Up Lessons From William Shatner's Failed Patent Bid
In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.
-
The Pros And Cons Of Levying Value-Based Fees On Patents
The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.
-
Series
Writing Musicals Makes Me A Better Lawyer
My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.
-
Between The Lines Of EPO's Adoption Of Color Drawings
The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.
-
What Prop 65 Ruling Means For Cosmetics, Personal Care Biz
A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.
-
Series
Adapting To Private Practice: From Va. AUSA To Mid-Law
Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.
-
2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.
-
Rebutting Price Impact In Securities Class Actions
Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.
-
7 Document Review Concepts New Attorneys Need To Know
For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.
-
Ruling On Labor Peace Law Marks Shift For Cannabis Cos.
Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.